China Biologic Products Hosts its First Forum for Strategy and Development

PRNewswire
Jul 16, 2009

TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC: CBPO) (BULLETIN BOARD: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Company hosted a forum of industry experts on July 10 - 11, 2009, at its headquarters in Tai'an, Shandong Province, to discuss future development strategies for the Company.

Experts from the bio-pharmaceutical industry included Mr. Zhongwei Zheng, head of the research and development center at the Institute of Blood Transfusion at the Chinese Academy of Medical Science, and Mr. Fengshan Wang, Dean of School of Pharmaceutical Sciences at the Shandong University. Messrs. Zheng and Wang and other domestic and international academics and experts, gathered together to discuss strategies for the development of the new China Biologic, which recently became the largest non-state-owned plasma-based pharmaceutical Company in China following the Company's acquisitions of Dalin Biologic Technologies and also its equity investment in Xi'an Huitian Blood Products.

The forum provided a platform for industry experts to discuss and provide advice to the Company that could create synergies among its subsidiaries including, the initiation of research and development of new drugs, efficient use of resources among the subsidiaries, quality control procedures during collection, production and distribution processes, and other expert opinions to create long term, sustainable growth for the Company.

"The forum has provided us with many strategic ideas to further the growth of the new China Biologic," said Mr. Chao Ming Zhao, CEO of China Biologic Products. "We look forward to implementing some of those strategies and create synergies among our subsidiaries."

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's blood products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its plasma-based biopharmaceutical products to hospitals and other healthcare facilities in China.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the Company's forum for strategy and development on the business and operations of the Company, including the ability of the Company to create synergies among its subsidiaries; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov/). All forward- looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

  For more information, please contact:

  Company Contact:
   Mr. Y. Tristan Kuo
   Chief Financial Officer
   China Biologic Products, Inc.
   Tel:   +86-538-6202206
   Email: IR@chinabiologic.com
   Web:   http://www.chinabiologic.com/

  Investor Relations Contact:
   Mr. Crocker Coulson, President
   CCG Investor Relations
   Tel:   +1-646-213-1915 (NY office) or
   Mr. Gary Chin
   Tel:   +1-646-213-1909
   Email: crocker.coulson@ccgir.com
   Web:   http://www.ccgirasia.com/

SOURCE: China Biologic Products, Inc.

CONTACT: Company Contact: Mr. Y. Tristan Kuo, Chief Financial Officer Of
China Biologic Products, Inc., +86-538-6202206, or IR@chinabiologic.com; Or
Investor Relations Contact: Mr. Crocker Coulson, President of CCG Investor
Relations, +1-646-213-1915 (NY office) or Mr. Gary Chin, +1-646-213-1909, or
crocker.coulson@ccgir.com

Web site: http://www.chinabiologic.com/
http://www.ccgirasia.com/


print email rss
© 2014 China Biologic Products, Inc. All Rights Reserved.